Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897621 · ClinicalTrials.gov registry record · NA
The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery
A NA study of Total Hip Arthroplasty and Tranexamic Acid, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03897621 is a NA study of Total Hip Arthroplasty and Tranexamic Acid that has completed, run by Thomas Jefferson University. The registered enrollment target is 50 participants, below the 141-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03897621, a NA study of Total Hip Arthroplasty and Tranexamic Acid, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currently based on a surgeon's preference. The objective of this study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal saline, will not be at risk, as at this time no data exists to determine which approach is safer or more effective. This is the first study to compare TXA vs. placebo in a double-blinded, randomized controlled trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2022-12-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897621
The ClinicalTrials.gov registry entry for NCT03897621 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (65% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Total Hip Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03897621 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03897621 about?
NCT03897621 is a clinical study titled "The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery". Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currentl...
What is the current status of trial NCT03897621?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-05-20. Estimated completion is 2022-12-20.
What conditions does trial NCT03897621 study?
This clinical trial studies the following conditions: Total Hip Arthroplasty, Tranexamic Acid, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Coagulation; Intravascular.
What interventions are being tested in trial NCT03897621?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT03897621?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897621 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Total Hip Arthroplasty
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
RECRUITING · NA
-
Patient Utilization of Opioid Destruction Bags in the Post-op Period
ACTIVE NOT RECRUITING · NA
-
Strength and Function Following Total Hip Arthroplasty
COMPLETED · NA
-
Improving Rehabilitation Outcomes After Total Hip Arthroplasty
COMPLETED · NA
-
Anterior Capsulectomy vs. Repair in Direct Anterior THA
COMPLETED · NA
-
RCT Foley Catheter Study for Elective TJA
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.